Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sleep protects against chemotherapy induced emesis.
Domínguez-Ortega L, Cubedo-Cervera R, Cortés-Funés H, Díaz-Gállego E. Domínguez-Ortega L, et al. Cancer. 1996 Apr 15;77(8):1566-70. doi: 10.1002/(SICI)1097-0142(19960415)77:8<1566::AID-CNCR21>3.0.CO;2-X. Cancer. 1996. PMID: 8608544 Clinical Trial.
Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
Abad A, Garcia P, Gravalos C, Tusquets I, Font A, Perez G, Cortés-Funes H, Fabregat X, Barnadas A, Rosell R. Abad A, et al. Cancer. 1995 Mar 15;75(6):1238-44. doi: 10.1002/1097-0142(19950315)75:6<1238::aid-cncr2820750605>3.0.co;2-p. Cancer. 1995. PMID: 7882275 Clinical Trial.
Protection against chemotherapy-induced emesis with sleep.
Dominguez-Ortega L, Cubedo-Cervera R, Diaz-Gallego E, Cortés-Funés H. Dominguez-Ortega L, et al. Lancet. 1994 May 21;343(8908):1298. doi: 10.1016/s0140-6736(94)92188-1. Lancet. 1994. PMID: 7910307 Clinical Trial. No abstract available.
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz-Rubio E, Cortes-Funes H, Conte PF, Dressler H. Fauser AA, et al. Eur J Cancer. 1996 Aug;32A(9):1523-9. doi: 10.1016/0959-8049(96)00132-3. Eur J Cancer. 1996. PMID: 8911112 Clinical Trial.
196 results